Early Results of First In Vivo Gene-Editing Trial Encouraging

Two patients who received Sangamo’s zinc finger–based treatment for Hunter syndrome have lower biomarkers of the condition, but no signs of new enzyme production.

Sep 5, 2018
Kerry Grens

ABOVE: The therapy targets a gene in the liver.

The first patients to have received a medium dose of a gene therapy based on in vivo gene editing have lower levels of sugar in their urine—a hopeful sign that the intervention for Hunter syndrome is working. However, clinicians did not observe an increase in levels of the enzyme they hoped to replace, Sangamo Therapeutics, which developed the treatment, reported today (September 5).

“I cannot absolutely say it’s a treatment effect,” study leader Joseph Muenzer of the University of North Carolina, Chapel Hill, tells the Associated Press. But he adds that the data are “really encouraging.” 

Hunter syndrome is a rare disease in which an enzyme deficiency leads to a buildup of complex polysaccharides. Those with the condition often die young.

See “First In Vivo Genome Editing to Be Tested in New Clinical Trial

The first person to have received the treatment got it back in November. The infusion includes a normally functioning gene for the dysfunctional enzyme and zinc finger nucleases to cut the genome and insert the gene. The treatment is targeted to the liver.

See “Man Receives First In Vivo Gene-Editing Therapy

In this latest trial, two people received a medium dose of the gene-editing reagents and two people, including the first patient, got a low dose. After 16 weeks, those who received the low dose experienced no change in their urine sugar levels. The medium-dose patients, on the other hand, saw three urine biomarkers—glycosaminoglycans, dermatan sulfate, and heparan sulfate—decline by 51 percent, 32 percent, and 61 percent, respectively.

Levels of iduronate-2-sulfatase, the enzyme targeted by the gene therapy, remained undetectable at the beginning and end of the trial’s assessments. Endpoints News reports that the result triggered a 22-percent drop in Sangamo’s stock this morning. The company says the lack of detectable enzyme doesn’t mean the gene therapy isn’t working.

“If longer-term data from this study continue to be positive, therapeutic genome editing has the potential to bring tremendous medical progress for [Hunter] and other monogenic diseases,” Edward Conner, chief medical officer of Sangamo, says in a press release sent to The Scientist.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets


Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!